The collaborative cardiovascular risk reduction in primary care (CCARP) study

Pharmacotherapy

Volumn 30, Issue 8, 2010, Pages 766-775

  Evans, Charity D ^a   Eurich, Dean T ^b   Taylor, Jeff G ^a   Blackburn, David F ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cardiovascular; Collaborative; Pharmacist; Primary care

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG USE; DRUG UTILIZATION; FEMALE; FOLLOW UP; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT COUNSELING; PHARMACIST; PILOT STUDY; PRIMARY MEDICAL CARE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE;

AGED; CARDIOVASCULAR DISEASES; COOPERATIVE BEHAVIOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHARMACISTS; PILOT PROJECTS; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; RISK REDUCTION BEHAVIOR;

EID: 77955434388     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.8.766     Document Type: Article

References (21)

1. Public Health Agency of Canada. Cardiovascular diseases - heart disease and stroke. Available from http://www.phacaspc.gc.ca/cd-mc/cvd-mcv/cvd- mortality-mcv-mortaliteeng.php. Accessed August 18, 2009.
2. Rabinowitz I, Tamir A. The SaM (screening and monitoring) approach to cardiovascular risk reduction in primary care: cyclic monitoring and individual treatment of patients at cardiovascular risk using the electronic medical record. Eur J Cardiovasc Prev Rehabil 2005;12:56-62.
3. Geber J, Parra D, Beckey N, Korman L. Optimizing drug therapy in patients with cardiovascular disease: the impact of pharmacist-managed pharmacotherapy clinics in a primary care setting. Pharmacotherapy 2002;22:738-47.
4. Carter B, Zillich A, Elliot W. How pharmacists can assist physicians with controlling blood pressure. J Clin Hypertens 2003;5:31-7.
5. Tsuyuki R, Johnson J, Teo K, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the study of cardiovascular risk intervention by pharmacists (SCRIP). Arch Intern Med 2002;162:1149-55.
6. Blackburn D, Evans C, Lamb D, Taylor J, Skilton K. Cardiovascular risk reduction strategies in community pharmacy settings need real world angle. CPJ 2007;140:295-7.
7. Carter B, Bergus G, Dawson J, et al. A cluster-randomized trial to evaluate physician/pharmacist collaboration to improve blood pressure control. J Clin Hypertens 2008;10:260-71.
8. McPherson R, Frohlich J, Fodor G, Genest J. Canadian Cardiovascular Society position statement: recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22:913-27.
9. Canadian Diabetes Association. 2003 clinical practice guidelines for the prevention and management of diabetes in Canada: targets for glycemic control. Can J Diabetes 2003;27:S18-20.
10. Hemmelgarn B, McAlister F, Grover S, et al. The 2006 Canadian hypertension education program recommendations for the management of hypertension. I. Blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2006;22:573-81.
11. Khan N, McAlister F, Rabkin S, et al. The 2006 Canadian hypertension education program recommendations for the management of hypertension. II. Therapy. Can J Cardiol 2006;22:583-93.
12. Chobanian A, Bakris G, Black H. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-72.
13. Nathan D, Buse J, Davidson M, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy - a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72.
14. Grundy S, Cleeman J, Merz C. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004;110:227-39.
15. Benner J, Glynn R, Mogun H, Neumann P, Weinstein M, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-61.
16. Wei L, Wang J, Thompson P, Wong S, Struthers A, MacDonald T. Adherence to statin treatment and readmission of patients after myocardial infarction: a six-year follow-up study. Heart 2002;88:229-33.
17. Gaede P, Vedel P, Larsen N, Jensen G, Parving H-H, Pederson O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.
18. Browner W, Newman T, Cummings S, Hulley S. Getting ready to estimate sample size: hypotheses and underlying principles. In: Hulley S, Cummings S, eds. Designing clinical research. Baltimore: Williams & Wilkins, 1988:128-38.
19. Grundy S, Pasternak R, Greenland P, Smith S, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Hearth Association and the American College of Cardiology. Circulation 1999;100:1481-92.
20. Lear S, Ignaszewski A, Linden W, et al. A randomized controlled trial of an extensive lifestyle management intervention (EMLI) following cardiac rehabilitation: study design and baseline data. Curr Control Trials Cardiovasc Med 2002;3:9-22.
21. Bozovich M, Rubino C, Edmunds J. Effect of a clinical pharmacist-managed lipid clinic on achieving national cholesterol education program low-density lipoprotein goals. Pharmacotherapy 2000;20:1375-83.